Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced participation in upcoming virtual investor conferences. Nello Mainolfi, PhD, Co-Founder, President, and CEO, will engage in fireside chats at:

• Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 9:50 a.m. ET
• Guggenheim Healthcare Talks on March 16, 2022, at 8:00 a.m. ET

Webcasts will be accessible in the Investors section of their website, with replays available for 90 days. Kymera is focused on targeted protein degradation to develop novel therapeutics for immune-inflammatory diseases and cancers.

WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences:  

• Cowen & Co. 42nd Annual Health Care Conference 2022: Fireside Chat with Nello Mainolfi, PhD, Co-Founder, President and CEO on March 8th at 9:50 a.m. ET  
• Guggenheim Healthcare Talks | Targeted Protein Degradation Day: Fireside Chat with Nello Mainolfi, PhD, Co-Founder, President and CEO on March 16th at 8:00a.m. ET  

Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 90 days.  

About Kymera Therapeutics  
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus™ platform is a powerful drug discovery engine, advancing novel small molecule therapies that harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutics designed to address the most intractable of pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.

Investor Contact:  
Bruce Jacobs  
Chief Financial Officer  
investors@kymeratx.com 
857-285-5300  

Chris Brinzey 
Managing Director, Westwicke  
chris.brinzey@westwicke.com  
339-970-2843  

Media Contact:  
Tyler Gagnon  
Director, Corporate Communications  
tgagnon@kymeratx.com  
508-904-944 

FAQ

When will Kymera Therapeutics participate in investor conferences?

Kymera Therapeutics will participate in the Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, and the Guggenheim Healthcare Talks on March 16, 2022.

Who will represent Kymera Therapeutics at the conferences?

Nello Mainolfi, PhD, Co-Founder, President, and CEO, will represent Kymera Therapeutics during the investor conferences.

Where can I watch the Kymera Therapeutics presentations?

The presentations will be available as webcasts in the Investors section of Kymera Therapeutics' website.

How long will the webcast replays be available for Kymera Therapeutics?

The webcast replays for Kymera Therapeutics will be available for approximately 90 days after the events.

What is the focus of Kymera Therapeutics' drug discovery?

Kymera Therapeutics focuses on targeted protein degradation to develop novel small molecule therapies for immune-inflammatory diseases and hematologic malignancies.